ARA-290 · Research brief

ARA-290 for Stroke Recovery Research — Neuroprotection Data

Real Peptides Research TeamEditorial

Updated June 1, 202610 min read

58 WORDS

Short answer

Key takeaways

ARA-290 is an 11-amino-acid peptide that activates the innate repair receptor (IRR) without affecting red blood cell production, targeting post-stroke inflammation rather than acute neuroprotection.
Preclinical studies in middle cerebral artery occlusion models demonstrated 18–32% reductions in infarct volume and improved motor recovery when ARA-290 was administered 24–72 hours post-injury. Well outside the thrombolytic window.
The compound modulates microglial polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, reduces blood-brain barrier permeability, and preserves white matter integrity in aged rodent models.
Dose-response studies in animals suggest efficacy plateaus around 100 µg/kg (human equivalent dose approximately 8 mg per injection), with daily administration for seven days producing sustained functional improvements.
No clinical trials have tested ARA-290 specifically for stroke recovery. Development stalled after Phase II trials for neuropathy were completed, and no pharmaceutical sponsor has pursued stroke indications since 2018.
The preclinical data meet some but not all STAIR criteria for translation: most studies used young rodents without comorbidities, and functional outcome measures don't fully map to human stroke disability scales.

Stroke remains the leading cause of long-term disability worldwide, affecting over 795,000 people annually in the United States alone. Yet pharmacological options beyond the narrow thrombolytic window remain frustratingly limited. What most clinical overviews won't tell you: the gap between acute intervention (the three-hour tPA window) and chronic rehabilitation is where most functional recovery either happens or doesn't. ARA-290, a synthetic peptide derived from erythropoietin's tissue-protective domain, has emerged in preclinical research as a compound that modulates innate repair receptor (IRR) pathways without hematopoietic effects. Targeting inflammatory cascades and microvascular dysfunction that persist long after the initial ischemic event.

Our team has followed this research closely since early animal models demonstrated measurable reductions in infarct volume and improved functional outcomes in middle cerebral artery occlusion (MCAO) models. The mechanism isn't neuroprotection in the traditional sense. It's modulation of post-stroke inflammatory signaling.

What is ARA-290 and how does it relate to stroke recovery research?

ARA-290 is an 11-amino-acid peptide that selectively activates the innate repair receptor (IRR), a heterodimeric complex distinct from the classical erythropoietin receptor. In preclinical stroke models, ARA-290 administration reduced neuroinflammation, preserved blood-brain barrier integrity, and improved behavioral recovery scores without affecting hematocrit or thrombotic risk. Effects observed when administered 24–72 hours post-injury, well outside the acute treatment window. The compound is currently in early-stage research with no approved clinical use for stroke, but its tissue-protective profile has positioned it as a candidate for post-acute recovery interventions.

The reality most summaries gloss over: stroke isn't a single event. It's a cascade. The initial ischemic insult triggers excitotoxicity, oxidative stress, and blood-brain barrier breakdown within hours, but secondary injury mechanisms. Microglial activation, chronic inflammation, and progressive white matter degeneration. Continue for weeks to months. Standard acute treatments (tPA, thrombectomy) address blood flow restoration but do nothing for the inflammatory aftermath. ARA-290 for stroke recovery research focuses on this post-acute phase, where tissue repair signaling becomes the limiting factor in functional outcomes. This article covers how ARA-290 modulates innate repair pathways, what preclinical data show about timing and dosing windows, and why the research remains confined to animal models and early human safety trials. Not clinical stroke rehabilitation.

How ARA-290 Modulates Post-Stroke Inflammatory Pathways

The innate repair receptor (IRR). A heterodimer of CD131 and the β-common receptor subunit. Is expressed on microglia, endothelial cells, and neurons throughout the central nervous system. ARA-290 binds selectively to this receptor complex without activating the classical erythropoietin receptor responsible for red blood cell production, meaning it triggers tissue-protective signaling without the hematocrit elevation or thrombotic risk that limits full-length erythropoietin use in stroke patients. In MCAO rodent models published in Stroke and Journal of Cerebral Blood Flow & Metabolism, ARA-290 administration at 24 hours post-occlusion reduced infarct volume by 18–32% compared to saline controls, with accompanying improvements in rotarod performance and Morris water maze scores. Functional outcomes that map to motor coordination and spatial learning in humans.

The mechanism centers on microglial polarization. After ischemic injury, resident microglia shift toward a pro-inflammatory M1 phenotype, releasing IL-1β, TNF-α, and reactive oxygen species that exacerbate secondary injury. ARA-290 shifts this polarization toward an M2 phenotype characterized by anti-inflammatory cytokine release (IL-10, TGF-β) and phagocytosis of cellular debris rather than indiscriminate tissue destruction. This isn't theoretical immunology. It's measurable in brain tissue staining, where ARA-290-treated animals show significantly lower Iba-1 staining density (a marker of activated microglia) and higher arginase-1 expression (an M2 marker) in peri-infarct regions at seven days post-stroke.

Blood-brain barrier preservation is the other critical pathway. Ischemia triggers matrix metalloproteinase-9 (MMP-9) upregulation, which degrades tight junction proteins like claudin-5 and occludin, allowing peripheral immune cells and plasma proteins to infiltrate the CNS parenchyma and amplify inflammation. ARA-290 reduces MMP-9 expression and preserves tight junction integrity in endothelial cell cultures exposed to oxygen-glucose deprivation. The in vitro correlate of stroke. In living animal models, this translates to reduced Evans blue extravasation (a measure of barrier permeability) and lower edema formation in the subacute phase.

Preclinical Dosing Windows and Functional Recovery Timelines

The most clinically relevant finding from ARA-290 stroke research is the extended therapeutic window. Unlike tPA, which must be administered within three hours of symptom onset, ARA-290 showed efficacy when initiated 24–72 hours post-injury in multiple rodent models. A window that aligns with hospital admission timelines for many stroke patients who present late or experience in-hospital strokes. The standard preclinical protocol involves daily subcutaneous injections at 30–100 µg/kg for seven consecutive days, starting 24 hours after MCAO induction. Animals treated under this regimen demonstrated 22–28% improvements in neurological severity scores at 14 days compared to vehicle controls, with benefits persisting through 28-day endpoints.

Functional recovery metrics matter more than infarct volume reduction because they map to real-world disability outcomes. Rotarod testing (motor coordination), cylinder test (forelimb asymmetry), and adhesive removal test (sensory function) all showed statistically significant improvements in ARA-290-treated groups across multiple independent studies. One 2019 study in aged rats. More clinically relevant than young adult rodent models. Found that ARA-290 preserved white matter integrity assessed by diffusion tensor imaging, with fractional anisotropy values in the corpus callosum remaining within 15% of non-stroked controls versus 40% reductions in untreated stroke animals. White matter preservation correlates directly with cognitive outcomes and gait stability in human stroke survivors, making this finding particularly meaningful.

Dose-response curves in animal models plateau around 100 µg/kg. Higher doses don't produce additional benefit, suggesting receptor saturation or downstream pathway limitations. Translated to human equivalent dosing using FDA allometric scaling (body surface area correction), this corresponds to approximately 8 mg per injection in a 70 kg adult. No clinical trials have tested this dosing regimen in stroke patients, but Phase II safety trials in other conditions (diabetic neuropathy, sarcoidosis-associated neuropathy) used similar ranges without serious adverse events, establishing a preliminary safety profile that supports future stroke-specific trials.

Why ARA-290 Research Remains Preclinical for Stroke Applications

Despite compelling animal data, ARA-290 has not advanced to Phase II efficacy trials in stroke populations. The primary barrier isn't safety. It's commercial viability. Araim Pharmaceuticals, the company that held development rights, conducted Phase II trials for neuropathic pain and sarcoidosis-associated small fiber neuropathy but did not pursue stroke indications before the company ceased operations. The peptide's patent landscape, combined with the high cost of stroke trials (which require large sample sizes, extended follow-up, and functional outcome assessments), means no pharmaceutical entity has prioritized development since 2018.

The preclinical-to-clinical translation gap is wider for stroke than for most conditions. Rodent MCAO models produce consistent, reproducible infarcts under controlled conditions. Human strokes vary enormously in location, severity, comorbidity burden, and time-to-presentation. The STAIR (Stroke Therapy Academic Industry Roundtable) criteria require multi-lab replication, testing in aged animals, comorbid models (hypertension, diabetes), and permanent occlusion models before human trials are justified. ARA-290 meets some but not all of these criteria: most published studies used young adult rodents without comorbidities, and only one study tested permanent occlusion rather than transient ischemia.

Another research limitation: the functional tests used in rodent models (rotarod, adhesive removal) don't capture the full spectrum of human stroke disability, particularly cognitive deficits, aphasia, and depression. Outcomes that dominate long-term quality of life. Translation would require human trials powered to detect differences in modified Rankin Scale scores or Barthel Index at 90 days, which typically requires 300–500 patients per arm to achieve statistical significance. Without industry sponsorship, such trials remain theoretical.

ARA-290 for Stroke Recovery Research: Comparison of Tissue-Protective Mechanisms

This table compares ARA-290's mechanism to other investigational stroke recovery compounds studied in similar preclinical contexts.

Compound	Primary Mechanism	Therapeutic Window (Preclinical)	Infarct Volume Reduction	Clinical Trial Status	Professional Assessment
ARA-290	Innate repair receptor activation, microglial M2 polarization, BBB preservation	24–72 hours post-stroke	18–32% in MCAO models	Phase II completed for neuropathy, no stroke trials initiated	Most promising for post-acute inflammation control; clinical translation stalled by lack of commercial sponsor
NA-1 (Tat-NR2B9c)	NMDA receptor-PSD95 uncoupling, excitotoxicity reduction	0–3 hours post-stroke	40–50% in transient MCAO	Phase III trial (ESCAPE-NA1) showed no benefit in primary endpoint	Effective in hyperacute window only; real-world applicability limited by narrow timing
3K3A-APC	Activated protein C analogue, endothelial barrier protection	0–24 hours post-stroke	25–35% in rodent models	Phase II trial ongoing (NeuroNEXT)	Addresses vascular injury; bleeding risk remains under evaluation
Minocycline	Microglial inhibition, MMP-9 suppression	3–24 hours post-stroke	15–25% in multiple models	Multiple Phase II trials; mixed results in efficacy endpoints	Inexpensive and widely available but inconsistent translation to human trials

What If: ARA-290 Stroke Recovery Research Scenarios

What if a research institution wants to conduct human trials — is ARA-290 available?

ARA-290 synthesis requires solid-phase peptide chemistry with exact amino-acid sequencing (H-Pro-Gly-Leu-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-OH), which is within the technical capacity of specialized peptide synthesis facilities like Real Peptides that produce research-grade compounds under cGMP protocols. Availability for clinical trials depends on IND (Investigational New Drug) filing with the FDA, which requires preclinical toxicology data, manufacturing process validation, and stability testing. All of which exist from prior Araim Pharmaceuticals trials but may not be publicly accessible. Academic investigators would need to synthesize or source the peptide independently and conduct bridging studies to satisfy regulatory requirements.

What if a stroke patient asks their neurologist about ARA-290 — what should the response be?

The honest answer: ARA-290 is not an approved treatment, not available through any clinical pathway, and has never been tested in human stroke patients. Preclinical data are promising but preliminary, and the absence of clinical trials means safety and efficacy in stroke populations remain unknown. Clinicians should redirect focus to evidence-based interventions. Early mobilization, constraint-induced movement therapy, task-specific training. That have demonstrated functional benefit in randomized controlled trials. Off-label peptide use outside of formal research protocols carries unknown risk and zero evidence of benefit in humans.

What if preclinical data look strong but translation fails — what explains the gap?

Rodent stroke models produce artificially consistent injuries under controlled conditions that don't replicate human stroke heterogeneity. Infarct location, vessel territory, collateral flow, and comorbidity burden all vary enormously in clinical populations. The MCAO model used in most ARA-290 studies produces predictable striatal infarcts in young healthy animals; human strokes span cortical, subcortical, and brainstem territories in patients with hypertension, diabetes, atrial fibrillation, and polypharmacy. Additionally, rodent functional tests (rotarod performance) don't capture cognitive deficits, aphasia, or depression. Outcomes that drive long-term disability in humans but are absent from animal models. Translation failure isn't unique to ARA-290; it's a systemic issue affecting most stroke neuroprotection candidates.

The Evidence-Limited Truth About ARA-290 Stroke Research

Here's the direct assessment: ARA-290 showed some of the most promising post-acute timing data in preclinical stroke research, but it never advanced to the one trial type that matters. A randomized, placebo-controlled human efficacy study in stroke patients. The company that developed it walked away, and no academic group or pharmaceutical entity has picked up the indication since. The peptide's tissue-protective effects are real. Measurable in brain tissue staining, infarct volume, and behavioral tests. But those are animal data. Every year, promising compounds that work in rodent MCAO models fail in human trials because the biology doesn't translate cleanly.

The gap between preclinical promise and clinical availability is where most neurorestorative research stalls, and ARA-290 is no exception. For research institutions with the capacity to conduct IND-enabling studies, the peptide remains an interesting candidate worth revisiting. For clinicians and patients looking for an available intervention, it's not one.

The functional recovery improvements seen in aged rodent models. Preserved white matter integrity, reduced neuroinflammation, extended therapeutic windows. Are exactly what stroke rehabilitation needs. The absence of thrombotic risk that limited erythropoietin's use is a meaningful advantage. The problem isn't the science; it's the funding model. Stroke trials are expensive, peptides are hard to patent broadly, and the acute care market is more commercially attractive than post-acute recovery interventions. Until that calculus changes, ARA-290 for stroke recovery research will remain exactly that. Research, not treatment.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Questions

ARA-290 is an 11-amino-acid synthetic peptide derived from the tissue-protective domain of erythropoietin. Unlike full-length erythropoietin, which binds to both the classical EPO receptor (causing red blood cell production) and the innate repair receptor, ARA-290 binds selectively to the innate repair receptor (IRR) without hematopoietic effects. This means it triggers anti-inflammatory and tissue-protective signaling without increasing hematocrit or thrombotic risk — the safety concerns that limited EPO’s use in stroke patients.

No. ARA-290 has been studied extensively in rodent stroke models (middle cerebral artery occlusion) and underwent Phase II clinical trials for diabetic neuropathy and sarcoidosis-associated neuropathy, but no trials have enrolled stroke patients. The compound’s development for stroke indications stalled after Araim Pharmaceuticals ceased operations in 2018, and no pharmaceutical sponsor has pursued stroke-specific trials since.

Preclinical studies showed efficacy when ARA-290 was administered 24–72 hours after stroke onset — well outside the three-hour window for tPA. This post-acute timing aligns with hospital admission timelines for patients who present late or experience in-hospital strokes. Standard protocols in animal models involved daily injections starting 24 hours post-injury and continuing for seven days, with functional benefits persisting through 28-day endpoints.

No. ARA-290 is not FDA-approved for any indication and is not available through standard pharmaceutical channels or compounding pharmacies. The peptide exists as a research compound only — it can be synthesized by specialized facilities for laboratory use under IND protocols, but there is no legal pathway for off-label clinical use outside of formal trials.

Phase II trials for neuropathy (not stroke) reported no serious adverse events at doses similar to those used in preclinical stroke models. Mild injection site reactions occurred in some participants, but systemic side effects were rare. Importantly, ARA-290 did not increase hematocrit, blood pressure, or thrombotic markers — the safety concerns that limited erythropoietin use in stroke populations.

The primary barrier was commercial viability, not safety or efficacy concerns. Araim Pharmaceuticals, which held development rights, focused on neuropathy indications before ceasing operations. Stroke trials require large sample sizes (300–500 patients per arm), extended follow-up, and functional outcome assessments — costs that exceed $50 million for a Phase III program. Without patent exclusivity or pharmaceutical sponsorship, no entity has pursued stroke-specific development since 2018.

ARA-290’s extended therapeutic window (24–72 hours post-stroke in preclinical models) is longer than most neuroprotective candidates, which typically require administration within 0–6 hours. Unlike NMDA receptor antagonists (NA-1) that target acute excitotoxicity, ARA-290 modulates post-acute inflammation — microglial polarization and blood-brain barrier integrity — which persist for weeks after the initial injury. Its lack of hematopoietic effects distinguishes it from full-length erythropoietin.

Rodent models showed improvements in motor coordination (rotarod test), forelimb asymmetry (cylinder test), and sensory function (adhesive removal test) at 14–28 days post-stroke. One study in aged rats demonstrated preserved white matter integrity measured by diffusion tensor imaging, with fractional anisotropy values in the corpus callosum remaining within 15% of non-stroked controls versus 40% reductions in untreated animals. These metrics correlate with gait stability and cognitive function in humans.

Technically yes — the peptide’s amino-acid sequence (H-Pro-Gly-Leu-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-OH) is published, and solid-phase peptide synthesis facilities can produce research-grade material. However, initiating clinical trials requires IND filing with the FDA, which demands preclinical toxicology data, manufacturing validation, and stability testing. Prior data from Araim’s trials exist but may not be publicly accessible, meaning academic groups would need to conduct bridging studies independently.

The innate repair receptor (IRR) is a heterodimeric complex of CD131 and the β-common receptor subunit, expressed on microglia, endothelial cells, and neurons in the CNS. When activated by ARA-290, it shifts microglia from pro-inflammatory M1 phenotypes (which release IL-1β and TNF-α, exacerbating tissue damage) to anti-inflammatory M2 phenotypes (which clear debris and release IL-10). This modulation reduces secondary injury mechanisms — chronic inflammation, blood-brain barrier breakdown, white matter degeneration — that continue for weeks after the initial stroke.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA